October 2009

New Videos: Stent OP Dr. Simka and Ultrasound Prof. Zamboni

New videos to venous Multiple Sclerosis are available:

  • Stent OP of Dr. Simka, Poland
  • CCSVI and Multiple Sclerosis of Prof. Zamboni

Neue Videos: Stent OP Dr. Simka und Ultraschall Prof. Zamboni

Neue Videos sind zur venösen Multiple Sklerose sind verfügbar:

  • Stent OP von Dr. Simka, Polen
  • CCSVI and Multiple Sclerosis von Prof. Zamboni

CCSVI Examination

Personal examination/treatment

The goal of this website is to track development, especially research. CCSVI is currently under research. Examination and treatments are not standard medical methods. Access to treatment for multiple sclerosis must be based on science, not hope. Unfortunately, the research is still in the beginning. There are no scientific publications about "stenting" and thus there is no valid experience on that. Stents could be risky in the long term. A treatment in foreign countries may have additional risks. After-care examination should not be forgotten. Treatments should only be done within good scientific studies in order to increase the knowlege rapidly for everyone. See at the following presented book "Testing Treatments".

Study announcement of University at Buffalo, New York

The University at Buffalo, NY announced the "combined transcranial and extracranial venous Doppler" (CTEVD) study. The goal is to check the results of Prof. Zamboni. Prof. Robert Zivadinov leads this study. The new study will involve 1,600 adults and 100 children. The cohort will be comprised of 1,100 patients who were diagnosed with possible or definite MS, 300 age-and-sex matched normal controls, and 300 patients with other autoimmune and neurodegenerative diseases.
Enrollment in the study has begun and will continue for two years. MS patients from across the U.S. are eligible to participate in the study.

Studien Ankündigung der University at Buffalo, New York

Die University at Buffalo, New York hat die "combined transcranial and extracranial venous Doppler" (CTEVD) Studie angekündigt. Das Ziel ist die Resultate von Prof. Zamboni zu überprüfen. Die Studie wird von Prof. Robert Zivadinov geleitet. Die neue Studie wird 1600 Erwachsene und 100 Kinder umfassen. Diese Personen teilen sich auf folgende Gruppen auf:

  • 1.100 Patienten mit möglicher oder gesicherter MS,
  • 300 alters- und geschlechtsbestimmte Kontrollpersonen und
  • 300 Patienten mit anderen Autoimmunerkrankungen und neurodegenerativen Erkrankungen.